ImmunityBio, NantKwest announced positive interim phase 1 safety data of hAd5 COVID-19 vaccine dose study

, ,

On Nov. 10, 2020, ImmunityBio and NantKwest, a clinical-stage, natural killer cell-based therapeutics company, announced they had administered their second-generation bivalent, human adenovirus (hAd5) COVID-19 vaccine candidate in a Phase 1 trial with no SAEs reported in the low dose cohort, safety assessments are ongoing for the high dose cohort.

The trial was being conducted at Hoag Hospital in Newport Beach, California, and had enrolled 20 volunteers across two dose levels.

Tags:


Source: Nantwest
Credit: